Intellia Therapeutics

Intellia Therapeutics

NTLA· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -22.9% in FY2025

John M. Leonard, M.D. is the CEO of Intellia Therapeutics and was paid $5.1M in FY2025 (Dec), down 67%.

Pay$100 in the stock at the end of FY20 → $17
CEO pay is from each Intellia Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1John M. Leonard, M.D.FY2025
  2. 2Edward J. Dulac IIIFY2025
  3. 3David Lebwohl, M.D.FY2025
  4. 4James Basta, J.D.FY2025
  5. 5Birgit Schultes, Ph.D.FY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Intellia Therapeutics paid its 5 named executives $12.8M in total in FY2025 (Dec). CEO John M. Leonard, M.D. was paid $5.1M of that.

Name
John M. Leonard, M.D.President, Chief Executive Officer
Edward J. Dulac IIIExecutive Vice President, Chief FinancialNot disclosed
David Lebwohl, M.D.Executive Vice President, Chief Medical Officer
James Basta, J.D.Executive Vice President, General Counsel and Corporate Secretary
Birgit Schultes, Ph.D.Executive Vice President, Chief Scientific OfficerNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers20

See all

The FY2025 (Dec) proxy of Intellia Therapeutics names 20 peer companies for pay. Among Intellia Therapeutics and these peers, CEO pay was 9th highest of 11 and total shareholder return was 10th highest of 11.

9th highest of 11in Intellia Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:

$4.6M$19.2M

10th highest of 11in Intellia Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:

$15$524

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Activity

  1. Pay
    Intellia Therapeutics CEO pay fell 67% to $5.1M. The stock fell 23% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Intellia Therapeutics General counsel pay fell 62% to $1.8M. The stock fell 23% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Intellia Therapeutics Executive Vice President, Chief Financial pay fell 68% to $2.2M. The stock fell 23% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Intellia Therapeutics Division head pay fell 64% to $2.0M. The stock fell 23% in FY2025 (Dec).
    DEF 14A
  5. Pay
    Intellia Therapeutics CEO pay rose 32% to $15.3M. The stock fell 62% in FY2024 (Dec).
    DEF 14A
  6. Pay
    Intellia Therapeutics Executive Vice President, Chief Scientific Officer pay rose 32% to $5.5M. The stock fell 62% in FY2024 (Dec).
    DEF 14A
  7. Pay
    Intellia Therapeutics Executive Vice President, Chief Scientific Officer pay fell 19% to $3.7M. The stock fell 70% in FY2022 (Dec).
    DEF 14A
  8. Pay
    Intellia Therapeutics General counsel pay rose 22% to $4.9M. The stock fell 62% in FY2024 (Dec).
    DEF 14A
  9. Pay
    Intellia Therapeutics General counsel pay fell 76% to $3.6M. The stock fell 70% in FY2022 (Dec).
    DEF 14A
  10. Pay
    Intellia Therapeutics CFO pay rose 16% to $4.4M. The stock fell 62% in FY2024 (Dec).
    DEF 14A
  11. Pay
    Intellia Therapeutics CFO pay fell 15% to $3.4M. The stock fell 70% in FY2022 (Dec).
    DEF 14A
  12. Pay
    Intellia Therapeutics Division head pay rose 31% to $5.6M. The stock fell 62% in FY2024 (Dec).
    DEF 14A
  13. Pay
    Intellia Therapeutics Division head pay fell 13% to $3.7M. The stock fell 70% in FY2022 (Dec).
    DEF 14A
  14. Pay
    Intellia Therapeutics CEO pay rose 15% to $11.7M. The stock fell 13% in FY2023 (Dec).
    DEF 14A
  15. Pay
    Intellia Therapeutics Executive Vice President, Chief Scientific Officer pay rose 13% to $4.2M. The stock fell 13% in FY2023 (Dec).
    DEF 14A
  16. Pay
    Intellia Therapeutics General counsel pay rose 10% to $4.0M. The stock fell 13% in FY2023 (Dec).
    DEF 14A
  17. Pay
    Intellia Therapeutics CFO pay rose 11% to $3.8M. The stock fell 13% in FY2023 (Dec).
    DEF 14A
  18. Pay
    Intellia Therapeutics Division head pay rose 15% to $4.3M. The stock fell 13% in FY2023 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 30, 2026FY2025
Annual report10-KFeb 26, 2026FY2025
Proxy statementDEF 14AApr 30, 2025FY2024
Annual report10-KFeb 27, 2025FY2024
Proxy statementDEF 14AApr 29, 2024FY2023
Annual report10-KFeb 22, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data